Concepedia

Publication | Open Access

Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <i>TP53</i>

DOIFull Paper Access

135

Citations

46

References

2021

Year

Mansoor N. Saleh, Manish R. Patel, Todd M. Bauer, Sanjay Goel, Gerald S. Falchook, Geoffrey I. Shapiro, Ki Y. Chung, Jeffrey R. Infante, Robert M. Conry, Guilherme Rabinowits,
Clinical Cancer Research

Abstract

ALRN-6924 was well tolerated and demonstrated antitumor activity.

References

YearCitations

Page 1